INARI MEDICAL

COMPANY PROFILE - May 2022

Extracting large clots from large vessels without the need for thrombolytics or ICU stay

Inari Medical is committed to treating and transforming the lives of patients suffering from venous diseases through pioneering devices specifically designed and purpose-built for the venous anatomy and its unique clot morphology

CURRENT MARKETS AND PRODUCTS

Offering highly differentiated products in the venous space, treating Deep Vein Thrombosis (DVT) and Pulmonary Embolism (PE)

PULMONARY EMBOLISM (PE)[1]

THE CHALLENGE:

- Blood clots break loose and travel into the lungs
- 3rd leading cause of cardiovascular death
- #1 cause of preventable death in hospitals
- 12-50% short-term mortality across massive and sub-massive PE

THE INARI SOLUTION:
The **FlowTriever®** System

- A large bore catheter-based aspiration and mechanical thrombectomy system designed to remove large clots from large venous vessels, the right heart, pulmonary arteries and the lungs
- In May of 2018, the FlowTriever System received FDA approved labeling, making it the first mechanical thrombectomy device indicated for the treatment of Pulmonary Embolism (PE)
- In January of 2021, FlowTriever received 510(k) market clearance from the U.S. FDA for Right Atrial Clot in Transit becoming the first thrombectomy system not requiring a cardiopulmonary bypass circuit for blood clots in the right atrium

DEEP VEIN THROMBOSIS (DVT)[2]

THE CHALLENGE:

- Blood clots form in the deep venous system
- Up to 50% of patients are expected to develop post-thrombotic syndrome (PTS), a chronic, lifestyle-limiting disease comprising swelling, pressure, chronic pain and ulcers

THE INARI SOLUTION:
The **ClotTriever®** System

- Designed to core, capture and remove large clots from large venous vessels
- In February of 2017, the ClotTriever System received 510(k) market clearance from the U.S. FDA for the non-surgical removal of thrombi and emboli from the peripheral vasculature

FINANCIAL PROFILE

Robust quarterly revenue growth with gross margins of >80%



1. Pulmonary Embolism in 2017: Increasing Options for Increasing Incidence', National Center for Biotechnology Information, May2017.
2. Kahn SR. Arch Intern Med 2004

FAST FACTS

PATIENT-FOCUSED
Pursuing extraordinary outcomes and improving the quality of life for patients since 2011

PRODUCT SIMPLICITY
Intuitive, easy-to-use, single-use devices that do not require capital equipment or the use of thrombolytic drugs

COMPELLING PROCEDURE ECONOMICS
Products designed or short, single sessions, eliminating the need for expensive thrombolytics which require costly ICU stays and carry risks of major bleeding

COMMITMENT TO CLINICAL DATA
Significant investment into real-world and broad evidence generation to drive adoption; studies and registries include FLARE, CLOUT, FLASH, FLAME, and PEERLESS

SCALING COMMERCIAL ORGANIZATION
Rapidly growing US sales team designed to help hospitals develop programs that systematically identify, triage and treat PE and DVT patients; international expansion commencing in Europe, Asia and Latin America

MARKET OPPORTUNITY
Combined addressable market of $5.8B in the US alone, plus significant international opportunity

MARQUEE MED TECH IPO
1st non-biotech IPO post COVID-19 outbreak, completed May, 2020

(NASDAQ: NARI)

CONTACT INFORMATION

6001 Oak Canyon, Ste #100 Irvine, CA 92618, U.S
Steinenbachgaesslein 49, 4051 Basel, Switzerland
info@inarimedical.com
inarimedical.com